Riyadh, Saudi Arabia — Jamjoom Pharma’s net profit rose 23.4% in Q2 2025 to SAR 132.02 million, up from SAR 106.95 million in Q2 2024. However, profits declined 15.9% from SAR 157.03 million in Q1 2025.
Jamjoom attributed the year-on-year growth to operational efficiency, disciplined cost control, and stronger profit margins. Q2 revenue climbed 14.6% to SAR 396.22 million, driven by performance in ophthalmology, dermatology, and general medicine across Saudi Arabia, the GCC, and Iraq. Institutional sales, new product launches, and improved commercial execution also contributed to this momentum.
Jamjoom Pharma Q2 Profit Boosted by Regional Sales Momentum
Revenue increased 14.6% year-on-year to SAR 396.22 million. The expansion across KSA, the Gulf, and Iraq—especially in core therapy areas—was a key driver of the Jamjoom Pharma Q2 profit increase. Institutional and export sales added meaningful support.
Jamjoom H1 Earnings Reflect Operational Efficiency and Cost Discipline
Net profit in H1 2025 surged 37.7% to SAR 289.06 million, up from SAR 209.9 million in the first half of 2024. Revenue growth across therapeutic categories, combined with tighter expense control, drove stronger margins and higher profitability.
What This Means for Investors
- Solid earnings growth: The Q2 uplift reflects effective execution in core markets and product segments.
- Operational discipline: Margin gains and cost control highlight management efficiency.
- Regional demand strength: Growth in the Gulf and Iraq markets enhances diversification.
- Resilience ahead: Despite the sequential dip in Q2, H1 results confirm a strong earnings trajectory.
THE SAUDI STANDARD’S VIEW: Jamjoom Pharma’s Profit Growth Signals Maturity of Saudi Healthcare Industry
Jamjoom Pharma’s 23.4% year-on-year profit rise in Q2 2025 to SAR 132.02 million—supported by strong sales across Saudi Arabia, the Gulf, and Iraq—underscores the growing regional presence and operational maturity of Saudi pharmaceutical firms.
- Healthcare Localization in Action: Jamjoom’s success reflects the Kingdom’s drive to localize pharmaceutical production. This aligns with Vision 2030’s broader goal of building resilient, self-sufficient healthcare supply chains. Its strong domestic showing reinforces Saudi Arabia’s emergence as a regional pharma hub.
- Therapeutic Diversification and Execution: Growth in ophthalmology, dermatology, and general medicine shows an agile portfolio strategy that responds to regional demand. This therapeutic diversification mirrors Saudi Arabia’s expanding healthcare system and demographic trends.
- Operational Excellence Drives Profitability: Improved profit margins stemmed from cost controls and stronger commercial execution. These are key traits of the Kingdom’s evolving private healthcare sector. Although Q2 saw a quarterly dip, H1 performance (+37.7% YoY) validates Jamjoom’s disciplined and scalable growth model.
- Regional Market Integration Expands Reach: With rising sales in the Gulf and Iraq, Jamjoom is using Saudi Arabia’s strategic location to strengthen its export footprint. This outward strategy supports Saudi trade diversification and boosts healthcare diplomacy.
In conclusion, Jamjoom Pharma’s performance reflects the progress of industrial and healthcare reforms under Vision 2030. It also signals the next chapter of Saudi pharmaceutical leadership—defined by innovation, regional exports, and therapeutic impact.
